Publicacions en col·laboració amb investigadors/es de Marche Polytechnic University (27)

2024

  1. Comparing Survival of Perihilar Cholangiocarcinoma After R1 Resection Versus Palliative Chemotherapy for Unresected Localized Disease

    Annals of Surgical Oncology, Vol. 31, Núm. 10, pp. 6495-6503

2022

  1. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry

    Journal of Hepatology, Vol. 76, Núm. 5, pp. 1109-1121

  2. TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation

    Journal of Hepatology, Vol. 77, Núm. 4, pp. 991-1004

2021

  1. Correction: Current and novel therapeutic opportunities for systemic therapy in biliary cancer (British Journal of Cancer, (2020), 123, 7, (1047-1059), 10.1038/s41416-020-0987-3)

    British Journal of Cancer

  2. Inhibition of NAE-dependent protein hyper-NEDDylation in cystic cholangiocytes halts cystogenesis in experimental models of polycystic liver disease

    United European Gastroenterology Journal, Vol. 9, Núm. 7, pp. 848-859

  3. Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models

    Journal of Hepatology, Vol. 74, Núm. 2, pp. 394-406

2020

  1. Cholangiocarcinoma 2020: the next horizon in mechanisms and management

    Nature Reviews Gastroenterology and Hepatology, Vol. 17, Núm. 9, pp. 557-588

  2. Italian Clinical Practice Guidelines on Cholangiocarcinoma – Part I: Classification, diagnosis and staging

    Digestive and Liver Disease, Vol. 52, Núm. 11, pp. 1282-1293

  3. Italian Clinical Practice Guidelines on Cholangiocarcinoma – Part II: Treatment

    Digestive and Liver Disease, Vol. 52, Núm. 12, pp. 1430-1442

  4. Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic liver disease: New therapeutic targets

    Liver International, Vol. 40, Núm. 7, pp. 1670-1685

2019

  1. Aging-Related Expression of Twinfilin-1 Regulates Cholangiocyte Biological Response to Injury

    Hepatology, Vol. 70, Núm. 3, pp. 883-898

  2. Wnt–β-catenin signalling in liver development, health and disease

    Nature Reviews Gastroenterology and Hepatology, Vol. 16, Núm. 2, pp. 121-136

2018

  1. Cholangiocytes in health and disease: From basic science to novel treatments

    Biochimica et Biophysica Acta - Molecular Basis of Disease

  2. Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1864, Núm. 4, pp. 1335-1344

  3. MicroRNA-506 promotes primary biliary cholangitis–like features in cholangiocytes and immune activation

    Hepatology, Vol. 67, Núm. 4, pp. 1420-1440

2017

  1. Bile Acids in Polycystic Liver Diseases: Triggers of Disease Progression and Potential Solution for Treatment

    Digestive Diseases, Vol. 35, Núm. 3, pp. 275-281

  2. New Advances in Polycystic Liver Diseases

    Seminars in Liver Disease

  3. Nlrp3 Activation Induces Il-18 Synthesis and Affects the Epithelial Barrier Function in Reactive Cholangiocytes

    American Journal of Pathology, Vol. 187, Núm. 2, pp. 366-376

  4. SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma

    Journal of Hepatology, Vol. 67, Núm. 1, pp. 72-83

  5. Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma

    Hepatology, Vol. 66, Núm. 4, pp. 1125-1143